Media
TARGETED ONCOLOGY: The first patient with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC) has been dosed with ELI-002 7P in the phase 2 AMPLIFY-7P study (NCT05726864), according to Elicio Therapeutics, Inc.
MEDICAL NEWS TODAY: Researchers are reporting that a new vaccine could help prevent the reemergence of colorectal and pancreatic cancer in high-risk people who have previously undergone cancer treatment.
Shubham Pant, Zev A. Wainberg, et al.
Nature Medicine
January 09, 2024
HEALTHDAY: Patients with the most common form of pancreatic cancer could benefit from an experimental therapeutic vaccine, a small new clinical trial shows.
INDEPENDENT: A new vaccine has shown “promising” signs of being able to prevent relapse of specific types of pancreatic and bowel cancers for people who have previously had surgery.
PHARMA'S ALMANAC: In 2023, the FDA released the draft guidance titled: “Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products.” This draft guidance provides insight into the FDA’s expectations for cell and gene therapy (CGT) developers regarding manufacturing changes and comparability assessments under chemistry, manufacturing, and control (CMC) requirements.
LIFE SCIENCE LEADER: Ten years ago, Pete DeMuth was wrapping up his Ph.D. in biological engineering at MIT. In parallel, the lab at MIT was watering the sprout of a biotech business rooted in a simple hypothesis—the idea that precisely targeting vaccines to the right location in the body is critical for generating robust immunity against cancer.
TARGETED ONCOLOGY: Innovative findings in the field of cancer vaccines were presented at the Society for Immunotherapy of Cancer (SITC), focusing on a novel technology directing vaccines into lymph nodes.
Steinbuck MP, Cabana-Puig X, Palmer E, et al.
Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Nov 1-5, 2023
San Diego, CA